These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
464 related articles for article (PubMed ID: 33962692)
1. Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome. Mayneris-Perxachs J; Cardellini M; Hoyles L; Latorre J; Davato F; Moreno-Navarrete JM; Arnoriaga-Rodríguez M; Serino M; Abbott J; Barton RH; Puig J; Fernández-Real X; Ricart W; Tomlinson C; Woodbridge M; Gentileschi P; Butcher SA; Holmes E; Nicholson JK; Pérez-Brocal V; Moya A; Clain DM; Burcelin R; Dumas ME; Federici M; Fernández-Real JM Microbiome; 2021 May; 9(1):104. PubMed ID: 33962692 [TBL] [Abstract][Full Text] [Related]
2. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642 [TBL] [Abstract][Full Text] [Related]
3. Integrated omics analysis unraveled the microbiome-mediated effects of Yijin-Tang on hepatosteatosis and insulin resistance in obese mouse. Lee JE; Lee SM; Jung J Phytomedicine; 2020 Dec; 79():153354. PubMed ID: 32992082 [TBL] [Abstract][Full Text] [Related]
4. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota. Han R; Qiu H; Zhong J; Zheng N; Li B; Hong Y; Ma J; Wu G; Chen L; Sheng L; Li H Phytomedicine; 2021 May; 85():153544. PubMed ID: 33773192 [TBL] [Abstract][Full Text] [Related]
5. Potential therapeutic implications of histidine catabolism by the gut microbiota in NAFLD patients with morbid obesity. Quesada-Vázquez S; Castells-Nobau A; Latorre J; Oliveras-Cañellas N; Puig-Parnau I; Tejera N; Tobajas Y; Baudin J; Hildebrand F; Beraza N; Burcelin R; Martinez-Gili L; Chilloux J; Dumas ME; Federici M; Hoyles L; Caimari A; Del Bas JM; Escoté X; Fernández-Real JM; Mayneris-Perxachs J Cell Rep Med; 2023 Dec; 4(12):101341. PubMed ID: 38118419 [TBL] [Abstract][Full Text] [Related]
6. Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease. Yu JS; Youn GS; Choi J; Kim CH; Kim BY; Yang SJ; Lee JH; Park TS; Kim BK; Kim YB; Roh SW; Min BH; Park HJ; Yoon SJ; Lee NY; Choi YR; Kim HS; Gupta H; Sung H; Han SH; Suk KT; Lee DY Clin Transl Med; 2021 Dec; 11(12):e634. PubMed ID: 34965016 [TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408 [TBL] [Abstract][Full Text] [Related]
8. Gut microbiome features and metabolites in non-alcoholic fatty liver disease among community-dwelling middle-aged and older adults. Zeng F; Su X; Liang X; Liao M; Zhong H; Xu J; Gou W; Zhang X; Shen L; Zheng JS; Chen YM BMC Med; 2024 Mar; 22(1):104. PubMed ID: 38454425 [TBL] [Abstract][Full Text] [Related]
9. Integrative metabolomics highlights gut microbiota metabolites as novel NAFLD-related candidate biomarkers in children. Luo J; Luo M; Kaminga AC; Wei J; Dai W; Peng Y; Zhao K; Duan Y; Xiao X; Ouyang S; Yao Z; Liu Y; Pan X Microbiol Spectr; 2024 Apr; 12(4):e0523022. PubMed ID: 38445874 [TBL] [Abstract][Full Text] [Related]
10. Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. Rom O; Liu Y; Liu Z; Zhao Y; Wu J; Ghrayeb A; Villacorta L; Fan Y; Chang L; Wang L; Liu C; Yang D; Song J; Rech JC; Guo Y; Wang H; Zhao G; Liang W; Koike Y; Lu H; Koike T; Hayek T; Pennathur S; Xi C; Wen B; Sun D; Garcia-Barrio MT; Aviram M; Gottlieb E; Mor I; Liu W; Zhang J; Chen YE Sci Transl Med; 2020 Dec; 12(572):. PubMed ID: 33268508 [TBL] [Abstract][Full Text] [Related]
11. Impact of Hypocaloric Hyperproteic Diet on Gut Microbiota in Overweight or Obese Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study. Pataky Z; Genton L; Spahr L; Lazarevic V; Terraz S; Gaïa N; Rubbia-Brandt L; Golay A; Schrenzel J; Pichard C Dig Dis Sci; 2016 Sep; 61(9):2721-31. PubMed ID: 27142672 [TBL] [Abstract][Full Text] [Related]
12. Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations. Ni Y; Qian L; Siliceo SL; Long X; Nychas E; Liu Y; Ismaiah MJ; Leung H; Zhang L; Gao Q; Wu Q; Zhang Y; Jia X; Liu S; Yuan R; Zhou L; Wang X; Li Q; Zhao Y; El-Nezami H; Xu A; Xu G; Li H; Panagiotou G; Jia W Cell Metab; 2023 Sep; 35(9):1530-1547.e8. PubMed ID: 37673036 [TBL] [Abstract][Full Text] [Related]
13. Zuogui-Jiangtang-Qinggan-Fang alleviates high-fat diet-induced type 2 diabetes mellitus with non-alcoholic fatty liver disease by modulating gut microbiome-metabolites-short chain fatty acid composition. Zou J; Xiang Q; Tan D; Shi L; Liu X; Wu Y; Yu R Biomed Pharmacother; 2023 Jan; 157():114002. PubMed ID: 36410120 [TBL] [Abstract][Full Text] [Related]
14. Monascus purpureus-fermented common buckwheat protects against dyslipidemia and non-alcoholic fatty liver disease through the regulation of liver metabolome and intestinal microbiome. Huang ZR; Chen M; Guo WL; Li TT; Liu B; Bai WD; Ai LZ; Rao PF; Ni L; Lv XC Food Res Int; 2020 Oct; 136():109511. PubMed ID: 32846589 [TBL] [Abstract][Full Text] [Related]
15. A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease. Petrov PD; García-Mediavilla MV; Guzmán C; Porras D; Nistal E; Martínez-Flórez S; Castell JV; González-Gallego J; Sánchez-Campos S; Jover R Mol Nutr Food Res; 2019 Oct; 63(20):e1900487. PubMed ID: 31322321 [TBL] [Abstract][Full Text] [Related]
16. Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease. Adams LA; Wang Z; Liddle C; Melton PE; Ariff A; Chandraratna H; Tan J; Ching H; Coulter S; de Boer B; Christophersen CT; O'Sullivan TA; Morrison M; Jeffrey GP Liver Int; 2020 Jun; 40(6):1356-1365. PubMed ID: 32243703 [TBL] [Abstract][Full Text] [Related]
17. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Jennison E; Byrne CD Clin Mol Hepatol; 2021 Jan; 27(1):22-43. PubMed ID: 33291863 [TBL] [Abstract][Full Text] [Related]
18. Obesity-associated deficits in inhibitory control are phenocopied to mice through gut microbiota changes in one-carbon and aromatic amino acids metabolic pathways. Arnoriaga-Rodríguez M; Mayneris-Perxachs J; Contreras-Rodríguez O; Burokas A; Ortega-Sanchez JA; Blasco G; Coll C; Biarnés C; Castells-Nobau A; Puig J; Garre-Olmo J; Ramos R; Pedraza S; Brugada R; Vilanova JC; Serena J; Barretina J; Gich J; Pérez-Brocal V; Moya A; Fernández-Real X; Ramio-Torrentà L; Pamplona R; Sol J; Jové M; Ricart W; Portero-Otin M; Maldonado R; Fernández-Real JM Gut; 2021 Dec; 70(12):2283-2296. PubMed ID: 33514598 [TBL] [Abstract][Full Text] [Related]
19. Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice. Porras D; Nistal E; Martínez-Flórez S; Olcoz JL; Jover R; Jorquera F; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S Mol Nutr Food Res; 2019 Apr; 63(8):e1800930. PubMed ID: 30680920 [TBL] [Abstract][Full Text] [Related]
20. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis. Wang P; Wang J; Li D; Ke W; Chen F; Hu X J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]